RenovoRx (RNXT) Enterprise Value (2020 - 2026)
RenovoRx (RNXT) posted Enterprise Value of -$12.4 million for Q1 2026, down 76.0% sequentially from -$7.0 million in Q4 2025, and up 15.22% YoY from -$10.7 million in Q1 2025.
RenovoRx (RNXT) Enterprise Value (2020 - 2026) Analysis & Trends
RenovoRx has reported Enterprise Value for 7 years, with the latest figure at -$12.4 million in Q1 2026.
- Quarterly Enterprise Value rose 15.22% year-over-year to -$12.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.4 million (up 15.22% YoY) and the FY2025 annual result came in at -$7.0 million, up 1.82% from the prior year.
- Enterprise Value declined to -$12.4 million in Q1 2026 per RNXT's latest filing, from -$7.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.2 million in Q4 2023 and troughed at -$14.6 million in Q1 2025.
- A 5-year average of -$8.3 million and a median of -$8.1 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 81.79% in 2023, then plunged 509.89% in 2024.
- Over 5 years, Enterprise Value stood at -$6.4 million in 2022, then surged by 81.79% to -$1.2 million in 2023, then slumped by 509.89% to -$7.2 million in 2024, then increased by 1.82% to -$7.0 million in 2025, then tumbled by 76.0% to -$12.4 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$12.4 million, -$7.0 million, and -$10.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 2.12 Bn |
| 10 | RenovoRx | 59.87 Mn | 59.87 Mn | 766,000.00 | -9.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.50 Mn |
| Mar 31, 2026 | -12.36 Mn |
| Dec 31, 2025 | -7.02 Mn |
| Sep 30, 2025 | -10.00 Mn |
| Jun 30, 2025 | -12.31 Mn |
| Mar 31, 2025 | -14.58 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Sep 30, 2024 | -9.56 Mn |
| Jun 30, 2024 | -11.74 Mn |
| Mar 31, 2024 | -4.39 Mn |
| Dec 31, 2023 | -1.17 Mn |
| Sep 30, 2023 | -3.20 Mn |
| Jun 30, 2023 | -5.95 Mn |
| Mar 31, 2023 | -3.72 Mn |
| Dec 31, 2022 | -6.44 Mn |
| Sep 30, 2022 | -8.11 Mn |
| Jun 30, 2022 | -10.77 Mn |
| Mar 31, 2022 | -13.12 Mn |
| Dec 31, 2021 | -15.19 Mn |
| Sep 30, 2021 | -17.70 Mn |